Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Goodwill (2021 - 2024)

Barinthus Biotherapeutics' Goodwill history spans 4 years, with the latest figure at $12.2 million for Q3 2024.

  • For Q3 2024, Goodwill changed 0.0% year-over-year to $12.2 million; the TTM value through Sep 2024 reached $12.2 million, changed 0.0%, while the annual FY2023 figure was $12.2 million, 0.0% changed from the prior year.
  • Goodwill reached $12.2 million in Q3 2024 per BRNS's latest filing, roughly flat from $12.2 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $12.6 million in Q4 2021 to a low of $12.2 million in Q4 2022.
  • Average Goodwill over 4 years is $12.3 million, with a median of $12.2 million recorded in 2022.
  • Peak YoY movement for Goodwill: dropped 3.33% in 2022, then changed 0.0% in 2023.
  • A 4-year view of Goodwill shows it stood at $12.6 million in 2021, then decreased by 3.33% to $12.2 million in 2022, then changed by 0.0% to $12.2 million in 2023, then changed by 0.0% to $12.2 million in 2024.
  • Per Business Quant, the three most recent readings for BRNS's Goodwill are $12.2 million (Q3 2024), $12.2 million (Q2 2024), and $12.2 million (Q1 2024).